Cerebral Pharmacokinetics of Imipramine in Rats After Single and Multiple Dosages

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 1981 Nov 1

PMID 7322212

Citations 18

Authors

W Daniel

A Adamus

M Melzacka

J Szymura

J Vetulani

Affiliations

Soon will be listed here.

Abstract

Pharmacokinetics of imipramine (IMI) and its active metabolite, desipramine (DMI) was studied in rats after administration of a single dose of 10 mg/kg IMI, or after chronic administration of this dose once or twice a day for 14 days. The elimination curves of IMI and DMI from the blood and brain show that both the whole body and the brain behave as multi-compartment systems. Maximum concentrations of IMI and DMI in blood and brain appear at the same time, indicating rapid metabolism of IMI: the concentrations were significantly higher in the brain than in the blood. After the chronic treatment the maximum blood and cerebral levels of IMI and DMI were not much higher than after a single dose, but the elimination was slowed down. Brain concentration of IMI and DMI and brain IMI/DMI concentration ratio do not parallel those in the blood. After a prolonged treatment, once or twice a day, desipramine in the brain is present for the whole period between injections at concentrations sufficient to inhibit the noradrenaline uptake. If the drug is given twice a day, in addition to DMI also IMI is present for the whole time at concentration which may inhibit also serotonin uptake.

Citing Articles

Physiologically Based Pharmacokinetic Model of Brain Delivery of Plasma Protein Bound Drugs.

Pardridge W Pharm Res. 2023; 40(3):661-674.

PMID: 36829100 PMC: 10036418. DOI: 10.1007/s11095-023-03484-2.

Different Classes of Antidepressants Inhibit the Rat α7 Nicotinic Acetylcholine Receptor by Interacting within the Ion Channel: A Functional and Structural Study.

Duarte Y, Rojas M, Canan J, Perez E, Gonzalez-Nilo F, Garcia-Colunga J Molecules. 2021; 26(4).

PMID: 33668529 PMC: 7918632. DOI: 10.3390/molecules26040998.

Repeated administration of imipramine modifies GABAergic transmission in rat frontal cortex.

Wabno J, Hess G J Neural Transm (Vienna). 2012; 120(5):711-9.

PMID: 23180303 PMC: 3631518. DOI: 10.1007/s00702-012-0919-3.

Bipolar disorder and mechanisms of action of mood stabilizers.

Rapoport S, Basselin M, Kim H, Rao J Brain Res Rev. 2009; 61(2):185-209.

PMID: 19555719 PMC: 2757443. DOI: 10.1016/j.brainresrev.2009.06.003.

Chronic imipramine but not bupropion increases arachidonic acid signaling in rat brain: is this related to 'switching' in bipolar disorder?.

Lee H, Rao J, Chang L, Rapoport S, Kim H Mol Psychiatry. 2008; 15(6):602-14.

PMID: 18982003 PMC: 2874651. DOI: 10.1038/mp.2008.117.

References

Vetulani J, Sulser F . Action of various antidepressant treatments reduces reactivity of noradrenergic cyclic AMP-generating system in limbic forebrain. Nature. 1975; 257(5526):495-6. DOI: 10.1038/257495a0. View

Potter W, Calil H, Manian A, Zavadil A, Goodwin F . Hydroxylated metabolites of tricyclic antidepressants: preclinical assessment of activity. Biol Psychiatry. 1979; 14(4):601-13. View

Buschsenschultz E, Pichot P, Boissier J . [Plasma levels of imipramine and desmethylimipramine and antidepressant effect during controlled therapy(author's transl)]. Psychopharmacologia. 1975; 41(2):187-95. DOI: 10.1007/BF00421078. View

Ross S, RENYI A . Tricyclic antidepressant agents. I. Comparison of the inhibition of the uptake of 3-H-noradrenaline and 14-C-5-hydroxytryptamine in slices and crude synaptosome preparations of the midbrain-hypothalamus region of the rat brain. Acta Pharmacol Toxicol (Copenh). 1975; 36(Suppl 5):382-94. DOI: 10.1111/j.1600-0773.1975.tb00806.x. View

DINGELL J, Sulser F, GILLETTE J . SPECIES DIFFERENCES IN THE METABOLISM OF IMIPRAMINE AND DESMETHYLIMIPRAMINE (DMI). J Pharmacol Exp Ther. 1964; 143:14-22. View

Gram L, Christiansen J . First-pass metabolism of imipramine in man. Clin Pharmacol Ther. 1975; 17(5):555-63. DOI: 10.1002/cpt1975175555. View

SHAND D, OATES J . Metabolism of propranolol by rat liver microsomes and its inhibition by phenothiazine and tricyclic antidepressant drugs. Biochem Pharmacol. 1971; 20(7):1720-3. DOI: 10.1016/0006-2952(71)90307-8. View

BREYER U . Perazine, chlorpromazine and imipramine as inducers of microsomal drug metabolism. Naunyn Schmiedebergs Arch Pharmacol. 1972; 272(3):277-88. DOI: 10.1007/BF00499039. View

BICKEL M, Weder H . The total fate of a drug: kinetics of distribution, excretion, and formation of 14 metabolites in rats treated with imipramine. Arch Int Pharmacodyn Ther. 1968; 173(2):433-63. View

10.

Perel J, STILLER R, Glassman A . Studies on plasma level/effect relationships in imipramine therapy. Commun Psychopharmacol. 1978; 2(5):429-39. View

11.

Cassano G, Hansson E . Autoradiographic distribution studies in mice with C14-imipramine. Int J Neuropsychiatry. 1966; 2(3):269-78. View

12.

Vetulani J, Stawarz R, DINGELL J, Sulser F . A possible common mechanism of action of antidepressant treatments: reduction in the sensitivity of the noradrenergic cyclic AMP gererating system in the rat limbic forebrain. Naunyn Schmiedebergs Arch Pharmacol. 1976; 293(2):109-14. DOI: 10.1007/BF00499215. View

13.

von Bahr C, Orrenius S, Sjoqvist F . Interaction of imipramine, desmethylimipramine, nortriptyline and 1-naphthol with microsomal preparations. Chem Biol Interact. 1971; 3(4):243-4. DOI: 10.1016/0009-2797(71)90043-3. View

14.

Ayd Jr F . Rational pharmacotherapy: once-a-day drug dosage. Dis Nerv Syst. 1973; 34(7):371-8. View

15.

Nagy A, Johansson R . Plasma levels of imipramine and desipramine in man after different routes of administration. Naunyn Schmiedebergs Arch Pharmacol. 1975; 290(2-3):145-60. DOI: 10.1007/BF00510547. View